Cargando…

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis

BACKGROUND: The clinical impact of neutralizing antibodies against interferon-beta (NAb) is controversial. Their presence can lead to a decrease in interferon-beta (IFNβ) efficacy. Fatigue reported in patients with multiple sclerosis (MS) may be associated with an unfavorable clinical course. We con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manceau, Philippe, Latarche, Clotilde, Pittion, Sophie, Edan, Gilles, de Sèze, Jérôme, Massart, Catherine, Debouverie, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256902/ https://www.ncbi.nlm.nih.gov/pubmed/25433670 http://dx.doi.org/10.1186/s12883-014-0215-y

Ejemplares similares

Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study
por: Nardin, Clotilde, et al.
Publicado: (2018)

No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients
por: Becker, Madlyne, et al.
Publicado: (2015)

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
por: Hyun, Jae-Won, et al.
Publicado: (2018)

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
por: Brochet, Bruno, et al.
Publicado: (2017)

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study
por: Leray, Emmanuelle, et al.
Publicado: (2015)

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
por: Tourbah, Ayman, et al.
Publicado: (2016)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Deficient Phosphorylation of Stat1 in Leukocytes Identifies Neutralizing Antibodies in Multiple Sclerosis Patients Treated with Interferon-Beta
por: Gavasso, Sonia, et al.
Publicado: (2014)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

Prognostic impact of epileptic seizures in multiple sclerosis varies according to time of occurrence and etiology
por: Selton, Marion, et al.
Publicado: (2022)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial
por: Metzger-Peter, Katline, et al.
Publicado: (2020)

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
por: Penner, Iris-Katharina, et al.
Publicado: (2012)

Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis
por: Link, Jenny, et al.
Publicado: (2014)

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis
por: Gauthier, Audrey, et al.
Publicado: (2021)

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France
por: Pivot, Diane, et al.
Publicado: (2016)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
por: Sbardella, Emilia, et al.
Publicado: (2009)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon
por: Zare, Nasrin, et al.
Publicado: (2013)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
por: Jeannin, S., et al.
Publicado: (2011)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
por: Edan, Gilles, et al.
Publicado: (2013)

Patient perceptions of multiple sclerosis and its treatment
por: de Seze, Jérôme, et al.
Publicado: (2012)

Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis
por: Lau, Alexander Y, et al.
Publicado: (2017)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
por: Simone, Isabella Laura, et al.
Publicado: (2006)

Beta-interferons in multiple sclerosis: A single center experience in India
por: Gupta, Salil, et al.
Publicado: (2010)

Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
por: Marziniak, Martin, et al.
Publicado: (2014)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013)

PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
por: Reuss, Reinhard
Publicado: (2013)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

Thrombotic microangiopathy associated with interferon-beta treatment in patients with multiple sclerosis
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2018)

The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)

Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
por: Elmazny, Alaa, et al.
Publicado: (2020)

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
por: Bachelet, Delphine, et al.
Publicado: (2016)

The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a
por: van Ballegooijen, Hanne, et al.
Publicado: (2022)

Mass Cytometry Identifies Expansion of T-bet(+) B Cells and CD206(+) Monocytes in Early Multiple Sclerosis
por: Couloume, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ncnqaod879r9nbakg1h63mac12